Abstract:
Objective To establish the normative and standard measures, to ensure medical safety and quality of care of the patients with Graves disease treated by 131I therapy.
Methods Formulating and strictly implementing the medical organizational and technical measures of 131I therapy for Graves disease and regular follow-up.
Results Receiving 131I treatment of 104 patients, follow-up 6-36 months, no adverse events, the cure rate of 59.6%, the efficient rate is 99.9%.
Conclusion It is important guarantee for the medical quality and safety to standardize the 131I therapy of Graves disease.